Plain-English translation of NCT06521476 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether a medication called can help people who have central sleep apnea (a condition where breathing stops during sleep) while they're taking medication to treat opioid addiction. Researchers believe that sleep apnea caused by opioid treatment medications may make recovery harder by increasing anxiety, affecting sleep quality, and triggering drug cravings. This trial will see if the medication can improve sleep and reduce these harmful effects.
Medications used to treat opioid addiction are known to sometimes cause sleep apnea, but doctors don't fully understand how much damage this causes or what to do about it. This study aims to find out whether this treatment can safely improve sleep and help people stay on track with their recovery.
You likely qualify if…
You likely don't qualify if…
You will come to a research facility for an overnight visit where doctors will monitor your sleep and test your heart function, anxiety levels, and thinking ability. Then you'll take either the medication or a placebo (inactive pill) for 7 days at home. Finally, you'll return for another overnight visit so researchers can see if the treatment helped improve your sleep and reduced anxiety or drug cravings.
AI-generated summary from trial data · Jun 23, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Sanjay R Patel
Collaborators
National Institute on Drug Abuse (NIDA)
Enrollment target
~40 participants
Started
September 2025
Primary completion
February 2028
Age range
18 Years – 100 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Madeline Gudobba
University of Pittsburgh
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.